Project Grant R01HL185314
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Galveston, TX 77555, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $246,000 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-specific differences in subclinical cardiovascular disease phenotypes and their relationship to psychosocial stress. The recipient will develop expertise in subclinical atherosclerosis measures and cardiovascular imaging phenotypes while examining whether chronic psychosocial...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $150,104 on March 2, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiovascular and respiratory responses to physical activity and heat stress in burn survivors. The recipient will conduct research on thermoregulation and pulmonary function impairment in burn survivors, who experience exaggerated increases in core...
- The National Heart, Lung, and Blood Institute awarded the University of Texas at Arlington $113,788 on August 14, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how changes in shared public activity spaces—such as walking trails, parks, and sidewalks—affect long-term hypertension risk trajectories in aging adults. The research uses longitudinal data from the nationally representative Health and Retirement Study to identify physical activity-related pathways...
- The National Heart, Lung, and Blood Institute awarded the University of Texas at Austin $238,858 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop personalized prediction models for HER2-induced cardiovascular adverse events in older women with breast cancer using artificial intelligence and machine learning. The award funds a cohort study using 2011–2022 Surveillance, Epidemiology, and End Results (SEER)–Medicare data linked with American...
- The National Heart, Lung, and Blood Institute awarded Duke University $136,646 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 19, 2025, to conduct a K01 Career Development Award examining sex differences in barriers and predictors of physical activity participation during and following cardiac rehabilitation. The award is structured as a Project Grant with performance through August 31, 2030, at Duke University in Durham, North Carolina. The recipient will...
- The National Heart, Lung, and Blood Institute awarded University of California, Los Angeles $236,250 on June 1, 2026, to develop an integrated psychotherapy intervention targeting posttraumatic stress disorder in cardiac patients, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development and pilot testing of Cardiac Fears Treatment (CFT), a streamlined intervention combining trauma-focused and interoceptive exposure therapies to address cardiac...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.272968 million on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-dependent regulation of cardiac cyclic AMP, excitation-contraction coupling, and arrhythmia by phosphodiesterases. The research addresses autonomic dysregulation and aberrant intracellular signaling in both heart failure with reduced ejection fraction and heart failure with...
- The National Heart, Lung, and Blood Institute awarded the University of Texas Health Science Center at Houston $794,406 on July 1, 2026, for a Project Grant (R01HL181234) to optimize and evaluate an implementation strategy to improve use of classroom-based physical activity approaches in elementary schools. This award is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will develop and refine a multifaceted implementation strategy designed to promote two...
- The National Institutes of Health National Heart Lung and Blood Institute awarded New York University $201,728 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research examining mechanisms contributing to functional recovery across the care cascade for respiratory failure. The research addresses how patient-level social determinants recorded at hospital admission, unit-level care processes during hospitalization, and community-level environmental...
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $608,173 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the stretch-activated PIEZO1 channel in heart failure-associated atrial fibrillation. The research comprises three aims: testing the hypothesis that atrial stretch-induced PIEZO1 activation contributes to pathological atrial remodeling and atrial fibrillation predisposition...